| Autor: |
Huntington SF; Yale School of Medicine, New Haven, CT, USA., Cheng WY; Analysis Group, Inc, Boston, MA, USA., Sarpong EM; Merck & Co., Inc, Rahway, NJ, USA., Leng S; Merck & Co., Inc, Rahway, NJ, USA., Farooqui MZH; Merck & Co., Inc, Rahway, NJ, USA., Agu US; University of Arizona, Tucson, AZ, USA., Catillon M; Analysis Group, Inc, Boston, MA, USA., Lejeune D; Groupe d'analyse, Ltée, Montréal, QC, Canada., Downes N; Analysis Group, Inc, Boston, MA, USA., Matay L; Analysis Group, Inc, Boston, MA, USA., Duh MS; Analysis Group, Inc, Boston, MA, USA., De Nigris E; MSD (UK) Limited, London, UK. |
| Abstrakt: |
With increasing focus on novel targeted therapies for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), this longitudinal claims-based study evaluated real-world CLL/SLL treatment sequences, particularly sequential targeted therapy. Among patients with first-line (1 L) treatment in 2014-2017 ( N = 2,612; median follow-up = 3 years), the most common 1 L treatment was chemoimmunotherapy (CIT; 44.6%), followed by CD20 (25.2%) and Bruton's tyrosine kinase inhibitors (BTKi; 21.7%). Among those with 1 L in 2018-2021 ( N = 4,534; median follow-up = 1 year), these were BTKi (45.5%), CD20 (20.4%), CIT (17.5%), and B-cell lymphoma 2 inhibitor (8.3%). In 2014-2017, the proportion of patients receiving sequential targeted therapy in the first 2 LOTs was 11.2% (80.2% was BTKi→BTKi); in 2018-2021, this proportion was 34.3% (66.4% was BTKi→BTKi). Over time, there was a substantial increase in targeted therapy use in 1 L and sequential targeted therapy, particularly with BTKi→BTKi. Future studies should assess clinical outcomes to determine optimal sequences for CLL/SLL and reasons for restarting BTKi. |
